{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:56:53Z","timestamp":1791341813202,"version":"4.3.1"},"reference-count":147,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Improving patient access to cancer clinical trials is a fundamental ASCO priority because clinical cancer research is the essential link transforming biomedical discoveries into meaningful progress in cancer care and patient outcomes. Today's standard of care emerged from yesterday's clinical trials. However, numerous barriers continue to threaten patient access to cancer clinical trials. This Special Report describes the essential role clinical trials play in improving cancer care and patient outcomes, current challenges in the design and conduct of clinical trials, and steps taken by ASCO to make clinical trials more accessible, patient-centered, and embedded within the communities where people live.<\/jats:p>","DOI":"10.1200\/op-25-00233","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T21:00:14Z","timestamp":1759784414000},"page":"1746-1758","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":7,"title":["ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States"],"prefix":"10.1200","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-1622","authenticated-orcid":true,"given":"Erin P.","family":"Balogh","sequence":"first","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-4229","authenticated-orcid":true,"given":"Laura A.","family":"Levit","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-0317","authenticated-orcid":true,"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-7279","authenticated-orcid":true,"given":"Melissa K.","family":"Accordino","sequence":"additional","affiliation":[{"name":"Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Chism","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-4964","authenticated-orcid":true,"given":"M. Kelsey","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-9858","authenticated-orcid":true,"given":"Helen M.","family":"Parsons","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9943-5762","authenticated-orcid":true,"given":"Manali I.","family":"Patel","sequence":"additional","affiliation":[{"name":"Stanford School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-6404","authenticated-orcid":true,"given":"Jeffery M.","family":"Peppercorn","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-8096","authenticated-orcid":true,"given":"Blase N.","family":"Polite","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-391X","authenticated-orcid":true,"given":"Mina S.","family":"Sedrak","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8592-2239","authenticated-orcid":true,"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[{"name":"University of Kansas, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-7911","authenticated-orcid":true,"given":"Ishwaria M.","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Medical Oncology and Palliative Care, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-5921","authenticated-orcid":true,"given":"Jennifer S.","family":"Temel","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0644-5572","authenticated-orcid":true,"given":"K. Robin","family":"Yabroff","sequence":"additional","affiliation":[{"name":"American Cancer Society, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-8545","authenticated-orcid":true,"given":"Raymond U.","family":"Osarogiagbon","sequence":"additional","affiliation":[{"name":"Baptist Cancer Center\u2014Memphis, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00754"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy221"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa155"},{"key":"e_1_3_5_5_2","volume-title":"A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program","author":"Institute of Medicine","year":"2010","unstructured":"Institute of Medicine: A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC, The National Academies Press, 2010"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23157"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae135"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33080"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21219"},{"key":"e_1_3_5_12_2","volume-title":"Addressing the Adverse Consequences of Cancer Treatment: Proceedings of a Workshop","author":"National Academies of Sciences E, and Medicine","year":"2022","unstructured":"National Academies of Sciences E, and Medicine: Addressing the Adverse Consequences of Cancer Treatment: Proceedings of a Workshop. Washington, DC, The National Academies Press, 2022"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041048"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4102"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041106"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45269"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12426-z"},{"key":"e_1_3_5_21_2","unstructured":"FDA: Oncology (cancer)\/hematologic malignancies approval notifications 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notifications"},{"key":"e_1_3_5_22_2","unstructured":"ASCO: ASCO guidelines methodology manual 2024. https:\/\/cdn.bfldr.com\/KOIHB2Q3\/as\/qr3pjw3xfmq2svntp76hpbm\/Guidelines-Methodology-Manual"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00248"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01324"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00886"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02245"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02133"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00762"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22515"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01030"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.025288"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912303412706"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5953"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju002"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.4155\/cli.14.21"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00261"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2055"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","unstructured":"2023 Snapshot: State of the Oncology Workforce in America. JCO Oncol Pract 21:438 2025","DOI":"10.1200\/OP.24.00262"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008520"},{"key":"e_1_3_5_41_2","volume-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","author":"National Academies of Sciences, Engineering, and Medicine","year":"2022","unstructured":"National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine, et al: Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington, DC, The National Academies Press, 2022"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2023.100435"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1854"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1547"},{"key":"e_1_3_5_45_2","volume-title":"Improving the Evidence Base for Treatment Decision Making for Older Adults With Cancer: Proceedings of a Workshop\u2014In Brief","author":"National Academies of Sciences, Engineering, and Medicine","year":"2021","unstructured":"National Academies of Sciences, Engineering, and Medicine: Improving the Evidence Base for Treatment Decision Making for Older Adults With Cancer: Proceedings of a Workshop\u2014In Brief. Washington, DC, The National Academies Press, 2021"},{"key":"e_1_3_5_46_2","volume-title":"Inclusion of Older Adults in Cancer Clinical Trials: Guidance for Industry","author":"FDA","year":"2022","unstructured":"FDA: Inclusion of Older Adults in Cancer Clinical Trials: Guidance for Industry. Silver Spring, MD, FDA, 2022"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0319"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21638"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa034"},{"key":"e_1_3_5_51_2","unstructured":"Vespoa J Medina L Armstrong DM: Demographic turning points for the United States: Population projections for 2020 to 2060. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2020\/demo\/p25-1144.pdf"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.105"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70488"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.5942"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/10748407221098187"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8739"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00662"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100026"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01214-5"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35145"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3852"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00961"},{"key":"e_1_3_5_64_2","unstructured":"National Cancer Institute: Who pays for clinical trials? 2024. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials\/paying"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01132"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae252"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0068"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33209"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00843"},{"key":"e_1_3_5_70_2","unstructured":"NCI: NCI's fiscal year 2024 budget challenges and interim paylines explained 2023. https:\/\/www.cancer.gov\/grants-training\/nci-bottom-line-blog\/2023\/nci-fy-2024-budget-challenges-and-interim-paylines-explained"},{"key":"e_1_3_5_71_2","unstructured":"NCI: NCI budget fact book 2024. https:\/\/www.cancer.gov\/about-nci\/budget\/fact-book"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.47894"},{"key":"e_1_3_5_73_2","unstructured":"National Center for Science and Engineering Statistics: Graduate enrollment in science engineering and health continues to increase among foreign nationals while postdoctoral appointment trends vary across fields 2024. https:\/\/ncses.nsf.gov\/pubs\/nsf24320\/"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.69"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6614a1"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1235"},{"key":"e_1_3_5_77_2","unstructured":"FDA: Advancing oncology decentralized trials 2024. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/advancing-oncology-decentralized-trials"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0850"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00702"},{"key":"e_1_3_5_80_2","unstructured":"VA: VA partnership with National Cancer Institute will boost Veteran access to clinical trials 2018. https:\/\/news.va.gov\/press-room\/va-partnership-with-national-cancer-institute-will-boost-veteran-access-to-clinical-trials\/"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usae441"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3924"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4553"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231204474"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.2.78"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00185"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02953"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00021"},{"key":"e_1_3_5_89_2","volume-title":"Cancer Clinical Trial Eligibility Criteria: Patients With HIV, Hepatitis B Virus, or Hepatitis C Virus Infections: Guidance for Industry","author":"FDA","year":"2020","unstructured":"FDA: Cancer Clinical Trial Eligibility Criteria: Patients With HIV, Hepatitis B Virus, or Hepatitis C Virus Infections: Guidance for Industry. Silver Spring, MD, FDA, 2020"},{"key":"e_1_3_5_90_2","volume-title":"Cancer Clinical Trial Eligibility Criteria: Brain Metastases: Guidance for Industry","author":"FDA","year":"2020","unstructured":"FDA: Cancer Clinical Trial Eligibility Criteria: Brain Metastases: Guidance for Industry. Silver Spring, MD, FDA, 2020"},{"key":"e_1_3_5_91_2","volume-title":"Cancer Clinical Trial Eligibility Criteria: Patients With Organ Dysfunction or Prior or Concurrent Malignancies: Guidance for Industry","author":"FDA","year":"2020","unstructured":"FDA: Cancer Clinical Trial Eligibility Criteria: Patients With Organ Dysfunction or Prior or Concurrent Malignancies: Guidance for Industry. Silver Spring, MD, FDA, 2020"},{"key":"e_1_3_5_92_2","volume-title":"Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients: Guidance for Industry and IRBs","author":"FDA","year":"2020","unstructured":"FDA: Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients: Guidance for Industry and IRBs. Silver Spring, MD, FDA, 2020"},{"key":"e_1_3_5_93_2","volume-title":"Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties","author":"FDA","year":"2024","unstructured":"FDA: Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties. Silver Spring, MD, FDA, 2024"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4186"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2023.06.002"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00429"},{"key":"e_1_3_5_97_2","unstructured":"FDA: Informed consent: Guidance for IRBs clinical investigators and sponsors 2023. https:\/\/www.fda.gov\/media\/88915\/download"},{"key":"e_1_3_5_98_2","unstructured":"ASCO: Insurance coverage of clinical trials 2025. https:\/\/www.asco.org\/research-data\/clinical-trials\/insurance-coverage-clinical-trials"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.22214"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01826"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303269"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30650-6"},{"key":"e_1_3_5_103_2","unstructured":"NCI: A commitment to early-stage investigators and community engagement by Dr. Diane Palmieri Director Center for Research Strategy 2024. https:\/\/www.cancer.gov\/grants-training\/nci-bottom-line-blog\/2024\/a-commitment-to-early-stage-investigators-and-community-engagement-nci-budget-proposal#:\u223c:text=NCI%20is%20the%20largest%20funder and%20treatment%20advances%20remain%20unrealized"},{"key":"e_1_3_5_104_2","unstructured":"NIH: Supplemental guidance to the 2024 NIH grants policy statement: indirect cost rates 2025. https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-25-068.html"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adw6467"},{"key":"e_1_3_5_106_2","unstructured":"Hudis C: https:\/\/cdn.bfldr.com\/KOIHB2Q3\/as\/kvk6bpf34kxqvwjphcsqt\/AAMC-Plaintiffs-Declarations-As-Filed"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.006"},{"key":"e_1_3_5_108_2","volume-title":"Physician-Scientist Workforce Working Group Report","author":"NIH","year":"2014","unstructured":"NIH: Physician-Scientist Workforce Working Group Report. Bethesda, MD, NIH, 2014"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200327"},{"key":"e_1_3_5_110_2","unstructured":"Parikh RB: This is why young academics are leaving for industry. Medscape Oncology 2022. https:\/\/www.medscape.com\/viewarticle\/968974"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1904482"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32982"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.41344"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00378"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3855"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3868"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3854"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3853"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4144"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7338"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.0761"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy169"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad237"},{"key":"e_1_3_5_124_2","unstructured":"ASCO: ASCO Targeted Agent and Profiling Utilization Registry Study 2025. https:\/\/www.tapur.org\/"},{"key":"e_1_3_5_125_2","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_126_2","unstructured":"ASCO: CDK4\/6 inhibitor dosing knowledge (CDK) study 2024. https:\/\/www.asco.org\/research-data\/cdk-study"},{"key":"e_1_3_5_127_2","unstructured":"ASCO: American Society of Clinical Oncology (ASCO) principles for the responsible use of artificial intelligence in oncology 2024. https:\/\/cdn.bfldr.com\/KOIHB2Q3\/as\/k7tmkvbmbkn3pm9hk4sn8jg\/ASCO-AI-Principles-2024"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02246"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00821"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.020313"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.6781"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.010975"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.008920"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00560"},{"key":"e_1_3_5_135_2","unstructured":"ASCO: Clinical trial eligibility criteria 2025. https:\/\/www.asco.org\/research-data\/clinical-trials\/clinical-trial-eligibility-criteria"},{"key":"e_1_3_5_136_2","unstructured":"Conquer Cancer: Increasing access to cancer care in rural Montana 2025. https:\/\/www.equityincancercare.org\/alliance-grantees\/asco\/"},{"key":"e_1_3_5_137_2","unstructured":"ASCO Connection: Increasing access to high-quality cancer care in rural communities 2024. https:\/\/connection.asco.org\/do\/increasing-access-high-quality-cancer-care-rural-communities"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00174"},{"key":"e_1_3_5_139_2","unstructured":"FDA: Master protocols: Efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and"},{"key":"e_1_3_5_140_2","unstructured":"FDA: Adaptive design clinical trials for drugs and biologics guidance for industry 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry"},{"key":"e_1_3_5_141_2","unstructured":"ASCO: Federally funded cancer research 2025. https:\/\/www.asco.org\/get-involved\/advocacy\/advocacy-agenda-initiatives\/federally-funded-cancer-research"},{"key":"e_1_3_5_142_2","unstructured":"ASCO: Setting the pace of progress: U.S. investment in cancer research saves lives 2024. https:\/\/cdn.bfldr.com\/KOIHB2Q3\/as\/8pkmqw9wmtvfjkfbtzf63g9j\/Clinical-Cancer-Advancement-Brochure-2024"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00501"},{"key":"e_1_3_5_144_2","unstructured":"ASCO: Career development 2025. https:\/\/www.asco.org\/career-development?cmpid=ma_ascoorg_mem_brand_em_asphonewsletter_pediatriconcologists_060122___careerdevelopment_aware_text_"},{"key":"e_1_3_5_145_2","unstructured":"AACR; ASCO: ASCO\/AACR methods in clinical cancer research workshop 2025. https:\/\/www.aacr.org\/meeting\/asco-aacr-methods-in-clinical-cancer-research-workshop-2025\/"},{"key":"e_1_3_5_146_2","unstructured":"Conquer Cancer: Grants & awards 2025. https:\/\/www.conquer.org\/cancer-research\/grants-awards?gad_source=1&gclid=CjwKCAiAhP67BhAVEiwA2E_9g4V0PJ20TNyRqHWtjlLZi4Mza0j0bwMUxEPPNzvk6mCtjHdKld4aKBoC5RoQAvD_BwE"},{"key":"e_1_3_5_147_2","unstructured":"ASCO: Medical student rotation 2025. https:\/\/www.asco.org\/career-development\/grants-awards\/funding-opportunities\/medical-student-rotation"},{"key":"e_1_3_5_148_2","unstructured":"ASCO: Leadership development program 2025. https:\/\/www.asco.org\/career-development\/leadership-programs\/leadership-development-program"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T22:59:41Z","timestamp":1765493981000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":147,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1200\/OP-25-00233"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00233","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}